ImClone Systems Inc (formerly IMCL)

[jbog]

Cork,

The phase I data that's been presented on CDP-791 actually showed that it performed well in RCC, and that's very unusual. It's a crowded space with sorenfib and stutent already being used in renal cell. I'm thinking imclone feels that lung was a premature target for the phase II trial.

1121-b has shown remarkable response so far as a mono, which is extremely unusual. Avastin never,ever showed anything as a mono.

Whats interesting today is that Eric basically said Avastin doesn't belong with folfox, and the trials are proving that. There are more dropouts in every trial, and the fda is aware of that.